Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Oct 25;9(11):1093.
doi: 10.1038/s41419-018-1147-z.

Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity

Yingying Wang  1   2 , Linlin Wu  3 , Haiyan Cai  1 , Hu Lei  1 , Chun-Min Ma  1 , Li Yang  1 , Hanzhang Xu  1 , Qi Zhu  2 , Zhujun Yao  4 , Yingli Wu  5
Affiliations
Comment

Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity

Yingying Wang et al. Cell Death Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

Figures

Fig. 1
Fig. 1. Model of the anti-MM effect of YL064.
Different from other kinds of cancer cells, the survival and proliferation of MM cells is highly dependent on the bone marrow microenvironment. Bone marrow stromal cells can confer drug resistance to MM cells through direct contact and/or releasing soluble factors such as IL-6. Consequently, STAT3 is activated by tyrosine phosphorylation (Tyr705), followed by homodimerization, nuclear translocation, DNA binding, and subsequent expression of numerous gene products required for tumor cell survival (e.g., Mcl-1), proliferation (e.g., cyclin D1). YL064 is a derivative of sinomenine, a natural compound in clinical use. YL064 directly interacts with STAT3 through its SH2 domains, which in turn inhibits the Tyr705 phosphorylation of STAT3, and ultimately represses the proliferation and viability MM cells in vitro and in vivo. YL064 is a promising novel candidate STAT3 inhibitor for the treatment of MM
See this image and copyright information in PMC

Comment on

References

    1. Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197–2208. doi: 10.1016/S0140-6736(14)60493-1. - DOI - PubMed
    1. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2016;91:719–734. doi: 10.1002/ajh.24402. - DOI - PMC - PubMed
    1. Kawano Y, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 2015;263:160–172. doi: 10.1111/imr.12233. - DOI - PubMed
    1. Forbes LR, Milner J, Haddad E. Signal transducer and activator of transcription 3: a year in review. Curr. Opin. Hematol. 2016;23:23–27. doi: 10.1097/MOH.0000000000000206. - DOI - PMC - PubMed
    1. Gallo LH, et al. Novel Lys63-linked ubiquitination of IKKbeta induces STAT3 signaling. Cell Cycle. 2014;13:3964–3976. doi: 10.4161/15384101.2014.988026. - DOI - PMC - PubMed

Publication types